GSK trades around GBX 1,754, after positive earnings and tuberculosis drug partnership

Traders Union
All News
Financial News
GSK slides 0.82% to GBX 1,754.00

Highlights

GSK plc trades at GBX 1,754.00, down 0.82%, remaining well above MA-20 at GBX 1,691.55, MA-50 at GBX 1,591.70, and MA-200 at GBX 1,472.54, confirming a strong multi-trend bullish structure.
Strong third quarter earnings and a new collaboration with AN2 Therapeutics, backed by Gates Foundation funding, reinforce GSK’s innovation and growth momentum.
Forecast for the next five trading days anticipates GBX 1,720–1,790 range, with over 80% probability of continued upside driven by bullish weekly indicators, but overbought signals suggest caution.

Earnings strength and partnerships fuel investor optimism

GSK's recent share price movement follows strong third quarter earnings results, underlining its performance in the current year. The company has also announced a collaboration with AN2 Therapeutics to develop boron-based LeuRS inhibitors for tuberculosis, backed by a third year of Gates Foundation funding. GSK's commitment to advancing pharmaceutical innovation and addressing global health challenges remains evident in these initiatives.

Divergent momentum as price nears overbought technical boundaries

GBX 1,754.00 remains well above the MA-20 at GBX 1,691.55, MA-50 at GBX 1,591.70, and MA-200 at GBX 1,472.54. This configuration confirms a persistent bullish structure across short-, medium-, and long-term trends, while the nearest dynamic support lies at Kijun, around GBX 1,695, and resistance is found near the MA-5 at GBX 1,776. Momentum indicators show some divergence. The daily MACD and ADX signal continued bullish momentum, but daily oscillators are mixed: RSI and CCI show bullish or overbought bias, while Stoch RSI and BBP highlight potential overbought conditions and short-term exhaustion. The Awesome Oscillator is neutral on the daily timeframe. The session opened slightly above the previous close with no significant gap. After slipping 0.82%, the current price is near today’s low from a range of GBX 1,753.50 — 1,773.50, reflecting moderate intraday volatility and ongoing pressure after the open. Intraday momentum signals are conflicted, suggesting some caution despite prevailing longer-term bullish signals.

Upside favored as weekly indicators support tight trading range

For the next 5 trading days, the expected range is adjusted to GBX 1,720 — 1,790. There is a very high probability (more than 80%) of continued upside, given strong bullish readings from weekly RSI, MACD, ADX, and MA-50, making further upward movement more likely than a reversal. The baseline scenario sees prices holding within a tight sideways corridor. A bullish scenario would occur if the price breaks and holds above resistance near GBX 1,776, possibly targeting higher round levels. Conversely, a bearish scenario would unfold if the price falls below support at GBX 1,695, exposing it to correction toward the next support levels.

Viktoras Karapetjanc, expert at Traders Union, sees GSK maintaining strong bullish momentum above key moving averages. He notes robust company fundamentals and positive sentiment, supported by recent earnings strength and the announced tuberculosis drug collaboration. According to Karapetjanc, technical signals and macro drivers both point to a sustained upside, with short-lived intraday volatility likely not disrupting the wider trend. He believes that as long as GBX 1,695 holds as support, confidence remains high for further gains. "I expect GSK to trade firmly within or above its current range, and see the risk-reward as skewed toward continued upside this week."

Previously it was noted that ongoing buyback activity and investor accumulation were offset by R&D pipeline risks in a period of low volatility. Technical analysis also demonstrated persistent bullish signals, though caution was advised due to mixed indicator readings and overbought momentum.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.